Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Sandra Naaman, George L. Bakris
Diabetes Care (2023) Vol. 46, Iss. 9, pp. 1574-1586
Open Access | Times Cited: 106

Showing 26-50 of 106 citing articles:

Benefits of Glucagon-like Peptide-1 Receptor Agonists after Kidney Transplantation
Sukhdeep Sahi, Oscar A. Garcia Valencia, Jie Na, et al.
Endocrine Practice (2025)
Closed Access
Finerenone: A Pillar for the Treatment of Diabetic Kidney Disease
Bharat Nathoo
(2025), pp. 2-2
Closed Access
GLP-1 Receptor Agonists for CKD: Remaining Issues or Mission Complete?
Vanja Kosjerina, Peter Rossing
American Journal of Kidney Diseases (2025)
Closed Access
Impact of Selective Peroxisome Proliferator-Activated Receptor (PPAR)-α Modulators and Fibrates on Microvascular Disease: Is There Still Room?
Lucas Lage Marinho, Maxance Ribeiro, Patrick R. Lawler, et al.
Current Atherosclerosis Reports (2025) Vol. 27, Iss. 1
Closed Access
Combining mitochondrial proteomes and Mendelian randomization to identify novel therapeutic targets for diabetic nephropathy
Yang Liu, Rong Wu, Zhenlei Zhou, et al.
Renal Failure (2025) Vol. 47, Iss. 1
Open Access
Novel Insights of Lithium Chloride Therapeutic Approach for Managing Type 2 Diabetic Kidney Disease: Crosslinking Tau Hyperphosphorylation and TGF Beta Signaling
Layal Abou Assi, Fatima Saleh, Mahmoud Khalil, et al.
Diabetology (2025) Vol. 6, Iss. 4, pp. 26-26
Open Access
TGF-β: elusive target in diabetic kidney disease
Priya Rani, Sindhura Lakshmi Koulmane Laxminarayana, Shilna Muttickal Swaminathan, et al.
Renal Failure (2025) Vol. 47, Iss. 1
Open Access
Using guideline-directed medical therapies to improve kidney and cardiovascular outcomes in patients with chronic kidney disease
Thelma Barber, Joshua J. Neumiller, Michelle A. Fravel, et al.
American Journal of Health-System Pharmacy (2025)
Closed Access
6. CARDIO-RENAL PROTECTION IN TYPE 2 DIABETES
Stephen Colagiuri, Antonio Ceriello
Diabetes Research and Clinical Practice (2025), pp. 112150-112150
Closed Access
How to Enhance Cardiorenal Benefits in Patients With Chronic Heart Failure?
Toshihide Izumida, Koichiro Kinugawa
International Journal of Heart Failure (2025) Vol. 7
Open Access
Trim33 inhibited the growth and relieved the fibrosis of mesangial cells through inducing the ubiquitination degradation of Smad2
Zhiyuan Liu, Yong Zhang, Hongzhou Li
Tissue and Cell (2025), pp. 102915-102915
Closed Access
Emerging Biomarkers and Innovative Therapeutic Strategies in Diabetic Kidney Disease: A Pathway to Precision Medicine
Sahana Shetty, Renuka Suvarna, Avivar Awasthi, et al.
Diagnostics (2025) Vol. 15, Iss. 8, pp. 973-973
Open Access
Effectiveness and safety of finerenone in Chinese CKD patients without diabetes: a retrospective, real-world study
Li Zhou, Wenge Li
International Urology and Nephrology (2024) Vol. 56, Iss. 12, pp. 3877-3885
Open Access | Times Cited: 4
The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease
M. Vasco, Samuel H. Fantaye, Sapna Raghunathan, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4135-4146
Open Access | Times Cited: 4
The efficacy and safety of Ginkgo biloba L. leaves extract combined with ACEI/ARB on diabetic kidney disease: a systematic review and meta-analysis of 41 randomized controlled trials
Zehua Zhang, Shiyun Tang, Shiyu Liu, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
The Role and Mechanism of Gut Microbiota in the Development of Diabetic Nephropathy
梅 韩
Advances in Clinical Medicine (2025) Vol. 15, Iss. 02, pp. 215-222
Closed Access
Klotho antiaging protein: molecular mechanisms and therapeutic potential in diseases
Aditya Dipakrao Hajare, Neha Dagar, Anil Bhanudas Gaikwad
Molecular Biomedicine (2025) Vol. 6, Iss. 1
Open Access
Canagliflozin improves fatty acid oxidation and ferroptosis of renal tubular epithelial cells via FOXA1-CPT1A axis in diabetic kidney disease
Tian Gan, Qingzhu Wang, Yi Song, et al.
Molecular and Cellular Endocrinology (2023) Vol. 582, pp. 112139-112139
Closed Access | Times Cited: 9
Potential kidney protective effects of glucagon‐like peptide‐1 receptor agonists
Philippa Trevella, Elif I. Ekinci, Richard J. MacIsaac
Nephrology (2024) Vol. 29, Iss. 8, pp. 457-469
Open Access | Times Cited: 3
Podocyte OTUD5 alleviates diabetic kidney disease through deubiquitinating TAK1 and reducing podocyte inflammation and injury
Ying‐Yong Zhao, Shijie Fan, Hong Zhu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Clinical trial designs of emerging therapies for DKD Clinical trial designs of emerging therapies for diabetic kidney disease (DKD)
Ajay Singh, Youssef M.K. Farag, Zihe Zheng, et al.
Postgraduate Medicine (2024) Vol. 136, Iss. 6, pp. 585-593
Closed Access | Times Cited: 3
Myricetin induces M2 macrophage polarization to alleviate renal tubulointerstitial fibrosis in diabetic nephropathy via PI3K/Akt pathway
Weilong Xu, Peipei Zhou, Yu Xu, et al.
World Journal of Diabetes (2024) Vol. 15, Iss. 1, pp. 105-125
Open Access | Times Cited: 2
Phloretamide Protects against Diabetic Kidney Damage and Dysfunction in Diabetic Rats by Attenuating Hyperglycemia and Hyperlipidemia, Suppressing NF-κβ, and Upregulating Nrf2
Rasha Al-Hussan, Nawal A. Albadr, Ghedeir M. Alshammari, et al.
Pharmaceutics (2024) Vol. 16, Iss. 4, pp. 505-505
Open Access | Times Cited: 2
Glucose to Complications: Understanding Secondary Effects in Diabetes Mellitus
Pranav Kumar Prabhakar
Sumatera Medical Journal (2024) Vol. 7, Iss. 2, pp. 87-95
Open Access | Times Cited: 2
Mineralocorticoid receptor antagonists and reno‐protection: What's the evidence & where do they fit? A guide for non‐specialists
George L. Bakris
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S6, pp. 33-42
Open Access | Times Cited: 2

Scroll to top